Plaquetec and Babraham Institute demonstrate druggability of pro-inflammatory protein for coronary artery disease

May 15, 2024

A collaboration between Plaquetec Ltd. and a lab at the Babraham Institute has demonstrated the druggability of a pro-inflammatory protein discovered by Plaquetec.

BioWorld Science Collaboration Cardiovascular

Today's news in brief

BioWorld

BioWorld briefs for April 16, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for April 16, 2025.

New Trump order zeroes in on drug prices

BioWorld

In a blast from the past, U.S. President Donald Trump signed an executive order April 15 to deliver on his 2016 campaign promises and strengthen or reinstate...

ADPD 2025: Novel treatment modalities in neurodegenerative disorders

BioWorld Science

The current treatment strategies for neurodegenerative diseases focus on targeting Aβ in Alzheimer’s disease (AD), α-synuclein aggregates in Parkinson’s disease...

Many US tariffs paused, pharma warned, EU put on notice

BioWorld

The on-again, off-again U.S. tariffs are off again, at least for now, for more than 75 countries that have reached out to the Trump administration to negotiate...